Prognostic value of baseline plasma p-tau217 for incident cognitive impairment in cognitively unimpaired cohorts: A systematic review and meta-analysis
Higher baseline plasma p-tau217 is a prognostic factor for broadly defined incident cognitive impairment in cognitively unimpaired adults, and evaluation of p-tau217 within multivariable prognostic models and trial-enrichment strategies is supported.
Abstract
Background Plasma phosphorylated tau 217 (p-tau217) is an accessible biomarker of Alzheimer's disease pathology, but its longitudinal association with incident cognitive impairment in cognitively unimpaired adults remains uncertain. Objective To quantify the prognostic association between baseline plasma p-tau217 and subsequent incident cognitive impairment. Methods Six databases and two trial registries were searched through July 2026 for longitudinal studies enrolling cognitively unimpaired adults with baseline plasma or serum p-tau217 and subsequent mild cognitive impairment, dementia, composite cognitive impairment, or sustained Clinical Dementia Rating progression. Adjusted hazard ratios (HRs) per 1-SD higher p-tau217 were pooled using random-effects restricted maximum likelihood with Hartung–Knapp inference. Heterogeneity and 95% prediction intervals were estimated. A post hoc sensitivity analysis excluded WHIMS. Results Six reports representing 16 cohorts were eligible; four reports contributed 13 independent cohort estimates comprising 6856 participants and 1939 events. Higher baseline p-tau217 was associated with greater hazard of incident cognitive impairment (HR 1.64, 95% CI 1.40–1.91; I2 = 88.9%; τ2 = 0.0424; 95% prediction interval 1.02–2.63). Excluding WHIMS, the association persisted across 12 cohorts and 4162 participants (HR 1.53, 95% CI 1.35–1.74; I2 = 63.6%; prediction interval 1.13–2.09). Conclusions Higher baseline plasma p-tau217 is a prognostic factor for broadly defined incident cognitive impairment in cognitively unimpaired adults. However, substantial heterogeneity, clinically distinct outcome definitions, and limited independent reports preclude interpreting the pooled HR as Alzheimer-specific progression or individual-level predictive performance. Future studies should prioritize standardized outcomes, assay harmonization, and externally validated absolute-risk models. These findings support evaluation of p-tau217 within multivariable prognostic models and trial-enrichment strategies.
Findings support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention in appropriately selected at-risk individuals before the onset of clinical symptoms and support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention.
Yue-Xuan Xu, T. I. Gunasekaran, Yian Gu et al.· Lancet Neurology· 1 citation
The findings indicate that a robust four-factor cognitive structure can be identified in clinically defined MCI cohorts without prior biological selection, and the association between latent memory factors and plasma p-tau217, observed primarily in cohorts with higher biomarker burden or clearer amnestic profiles, high...
Ana S. Perez, Hugo L. Hammer, V. Andersson et al.· GeroScience· 0 citations
Greater ten-year ASCVD risk was consistently associated with cognitive impairment independent of plasma AD biomarkers, with evidence that p-tau181 modifies these associations and that their magnitude varies across racial and ethnic groups.
J. Contreras, N. Ortega, Raymond Jones et al.· Frontiers in Aging Neuroscie...· 0 citations
It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...
B. Bellaver, G. Povala, P. C. L. Ferreira et al.· Molecular Neurodegeneration· 0 citations
These findings support the use of blood-based biomarkers for population-level dementia risk stratification, underscore the value of combining markers to improve prognostic precision, and can aid clinicians using plasma p-tau217 or NfL in interpreting dementia risk.
A. Sunde, D. Tovar-Rios, A. Vik-Mo et al.· medRxiv· 0 citations
These findings support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment and support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment.
R. Shi, L. Choity, S. Brodman et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.